Zevra Therapeutics, a leading biopharmaceutical company, recently released its first-quarter 2026 financial results, showcasing impressive growth and progress in its key programs. The company reported a net revenue of $36.2 million, which represents a significant 78% increase from the previous year. This growth was driven by the strong performance of its NPC therapy MIPLYFFA, as well as contributions from its Global Expanded Access Program (EAP) and the successful sale of its SDX portfolio.
MIPLYFFA, the company’s flagship product for Niemann-Pick disease type C (NPC), continues to gain momentum in the market. With 170 prescription enrollment forms submitted through March 31, MIPLYFFA has established itself as a key player in the NPC treatment landscape. The therapy has also received orphan drug designation in the U.S., providing marketing exclusivity through 2031. Zevra is actively pursuing a patent term extension that could further extend its exclusivity beyond that timeframe.
In addition to its commercial success, Zevra is making significant strides in its late-stage pipeline, particularly with its Phase III DiSCOVER trial of celiprolol for vascular Ehlers-Danlos syndrome (vEDS). The company has enrolled 62 patients in the trial and has reported positive interactions with the FDA regarding the development of this potential treatment option for vEDS patients.
Financially, Zevra is in a strong position, with $236.8 million in cash and investments and no outstanding debt as of March 31, 2026. The company recently retired its debt through the sale of its SDX portfolio, which generated a one-time gain of approximately $43.3 million. This move not only strengthened Zevra’s financial position but also allowed the company to focus on its core strategic priorities.
Looking ahead, Zevra’s management team is optimistic about the company’s future growth prospects. CEO Neil McFarlane emphasized the company’s commitment to building a durable rare disease company and expanding its impact in the global healthcare market. With a clinically meaningful product portfolio, a robust late-stage pipeline, and a strong financial foundation, Zevra is well-positioned to drive further growth and innovation in the biopharmaceutical industry.
In conclusion, Zevra Therapeutics continues to demonstrate its leadership in the rare disease space, with strong financial performance, commercial success, and a promising pipeline of innovative therapies. As the company continues to execute on its strategic priorities and expand its global reach, investors can expect to see continued growth and value creation from this dynamic biopharmaceutical company.
